Robert J. Motzer, MD, discusses the significance of the belzutifan plus lenvatinib approval, adverse event management with the combination, and the evolving role of HIF-2α inhibition in ccRCC.
|Videos|July 22, 2022
Dr. Alam on survival differences in kidney cancer based on race and socioeconomic factors
Author(s)Urology Times staff
Advertisement
Ridwan Alam, MD, a urology resident at Johns Hopkins Brady Urological Institute, discusses the abstract, “Investigation of race and associated socioeconomic factors in survival outcomes for patients with renal cell carcinoma,” which he presented at the 2022 AUA Annual Meeting (
Advertisement
Related to this article
The approval is supported by data from the phase 3 LITESPARK-011 trial.
Advertisement
Advertisement
Trending on Urology Times
1
John Sfakianos, MD, on integrating ctDNA into bladder cancer trials
2
AMA issues Category I CPT codes for implantable tibial neuromodulation in UUI
3
FDA updates in urology: September 2026
4
Enzalutamide plus salvage radiotherapy associated with improved PFS in high-risk BCR
5